Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)
April 21 2020 - 6:11AM
Edgar (US Regulatory)
Filed
by Ritter Pharmaceuticals, Inc. pursuant to
Rule
425 under the Securities Act of 1933
and
deemed filed pursuant to Rule 14a-6
under
the Securities Exchange Act of 1934
Subject
Company: Ritter Pharmaceuticals, Inc. (SEC File No. 001-37428)
Commission
File No. for the Related Registration Statement: 333-236235
Dear
Ritter Pharmaceuticals, Inc. Stockholder,
You
recently received proxy materials pertaining to certain matters related to Ritter Pharmaceuticals, Inc.’s (“Ritter”)
proposed merger with Qualigen, Inc., including notice of our Special Meeting of Stockholders, details on the merger and a request
for you to vote.
TO
DATE YOUR PROXY VOTE HAS NOT BEEN RECEIVED
Our
Board of Directors unanimously recommends that you vote “FOR” each of the Merger Proposals and we urge you to take
ACTION and VOTE now. PLEASE NOTE: PROPOSAL NOS. 1 THROUGH 4 MUST EACH BE APPROVED FOR THE MERGER TO TAKE PLACE.
You
are receiving this reminder email and request to vote because you held shares of Ritter as of the close of business on March 26,
2020, the record date for the Special Meeting. Our Special Meeting of Stockholders will be held virtually on May 14, 2020, at
9:00 a.m., Pacific Time. However, you can easily vote now, and we encourage you to do so.
|
HOW
TO VOTE NOW
|
|
WHAT
DO I NEED TO VOTE ON?
|
|
|
|
|
●
|
ONLINE:
Click the link in the email and follow the instructions to use your control number to vote your shares.
|
|
Each
of Proposal items: 1, 2, 3 and 4 are conditioned upon each other. Therefore, the merger
cannot be consummated without the approval of EACH of Proposal Nos. 1, 2, 3 and 4. Your
failure to vote FOR EACH of the proposals, or your decision to abstain from voting, will
have the same effect as a vote AGAINST the Merger Proposals, which will, collectively,
have the effect of voting AGAINST the merger.
To
better understand the merger and the proposals being considered and voted upon, please carefully read the entire joint
proxy and consent solicitation statement/prospectus and other materials that can be found on our
website:www.ritterpharmaceuticals.com/investors/sec-filings-2
|
|
|
|
●
|
CALL:
(866) 357-4029 to Vote NOW.
|
|
|
|
|
●
|
MAIL:
Complete, sign and date the enclosed proxy card and mail it in the enclosed postage-paid envelope as soon as possible.
|
|
|
|
|
●
|
ASSISTANCE:
If you have questions or require assistance in voting your proxy, please call our proxy solicitor Georgeson toll-free
at (866) 357-4029 or email info@ritterpharma.com for assistance.
|
|
REASONS
TO VOTE “FOR” THE MERGER PROPOSALS
●
|
The
merged company will focus on the development of Qualigen’s nanotechnology therapies for the treatment of cancer and
infectious diseases, while continuing to operate its revenue-generating diagnostic business.
|
|
|
●
|
Ritter
shareholders will own 7.5% of the post-merger company and will receive Contingent Value Rights (CVRs), entitling them to a
portion of the net proceeds from any potential monetization event involving all or any part of Ritter’s RP-G28 intellectual
property or technology.
|
|
|
●
|
If
the merger is not approved and consummated, it is likely that Ritter will be involuntarily delisted from Nasdaq and Ritter
may be forced to dissolve and liquidate its assets.
|
HOW
TO ATTEND THE SPECIAL MEETING?
Attend
the Special Meeting of Ritter Stockholders virtually by visiting www.virtualshareholdermeeting.com/RTTR2020 on the date of the
meeting. To be admitted to the virtual meeting, stockholders must enter the control number found on their proxy card or voting
instruction form. Once admitted, stockholders will be able to vote their shares electronically and submit any questions during
the meeting.
Sincerely,
Andrew
J. Ritter
Chief
Executive Officer
Ritter
Pharmaceuticals, Inc.
Important
Additional Information About the Proposed Merger
This
communication is being made in respect of the proposed merger involving Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Ritter
filed a registration statement on Form S-4 (File No. 333-23635) with the SEC. The Registration Statement on Form S-4 was declared
effective on April 9, 2020. The final joint proxy and consent solicitation statement/prospectus was filed with the SEC on April
9, 2020 and was first sent to the stockholders of Ritter and Qualigen on or about April 9, 2020. The final joint proxy and consent
solicitation statement/prospectus contains important information about Ritter, Qualigen, the proposed merger and related matters.
STOCKHOLDERS ARE URGED TO READ THE FINAL JOINT PROXY AND CONSENT SOLICITATION STATEMENT/PROSPECTUS (INCLUDING ANY AMENDMENTS OR
SUPPLEMENTS) AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY, AS THEY CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS
SHOULD CONSIDER BEFORE MAKING A DECISION ABOUT THE MERGER AND RELATED MATTERS. In addition to receiving the final joint proxy
and consent solicitation statement/prospectus and proxy card or voting instruction form by mail, stockholders will also be able
to obtain the final joint proxy and consent solicitation statement/prospectus, as well as other filings containing information
about Ritter, without charge, from the SEC’s website (http://www.sec.gov) or, without charge, by directing a written request
to: Ritter Pharmaceuticals, Inc., 1880 Century Park East, Suite 1000, Los Angeles, CA 90067, Attention: Corporate Secretary.
No
Offer or Solicitation
This
communication shall not constitute an offer to sell, the solicitation of an offer to sell or an offer to buy or the solicitation
of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer
of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933,
as amended.
Participants
in the Solicitation
Ritter
Pharmaceuticals, and its directors and executive officers, may be deemed to be participants in the solicitation of proxies from
the stockholders of Ritter Pharmaceuticals in connection with the proposed merger. Information regarding the special interests
of these directors and executive officers in the proposed merger has been included in the joint proxy and consent solicitation
statement/prospectus. Additional information about Ritter Pharmaceuticals’ directors and executive officers is included
in Ritter Pharmaceuticals’ definitive proxy statement, filed with the SEC on April 26, 2019. These documents are available
free of charge at the SEC website (www.sec.gov) and from the Corporate Secretary of Ritter Pharmaceuticals at the address above.
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Sep 2023 to Sep 2024